title: Targeted precise quantification of 12 human recombinant uridine-diphosphate glucuronosyl transferase 1A and 2B isoforms using nano-ultra-high-performance liquid chromatography/tandem mass spectrometry with selected reaction monitoring.
abstract: Quantification methods employing stable isotope-labeled peptide standards and liquid chromatography-tandem mass spectrometry are increasingly being used to measure enzyme amounts in biologic samples. Isoform concentrations, combined with catalytic information, can be used in absorption, distribution, metabolism, and excretion studies to improve accuracy of in vitro/in vivo predictions. We quantified isoforms of uridine-diphosphate glucuronosyltransferase (UGT) 1A and 2B in 12 commercially available recombinant UGTs (recUGTs) (n = 49 samples) using nano-ultra-high-performance liquid chromatography-tandem mass spectrometry with selected reaction monitoring). Samples were trypsin-digested and analyzed using our previously published method. Two MRMs were collected per peptide and averaged. Where available, at least two peptides were measured per UGT isoform. The assay could detect UGTs in all recombinant preparations: recUGTs 1A1, 1A3, 1A4, 1A6, 1A7, 1A8, 1A9, 1A10, 2B4, 2B7, 2B15, and 2B17, with limit of detection below 1.0 pmol/mg protein for all isoforms. The assay had excellent linearity in the range observed (2-15.5 pmol/mg, after dilution). Examples of concentrations determined were 1465, 537, 538, 944, 865, 698, 604, 791, 382, 1149, 307, and 740 pmol/mg protein for the respective isoforms. There was a 6.9-fold difference between the maximum and minimum recUGT concentrations. The range of concentrations determined indicates that catalytic rates per mg total protein in vitro will not accurately reflect isoform inherent specific activity for a particular drug candidate. This is the first report of a targeted precise quantification of commercially available recUGTs. The assay has potential for use in comparing UGT amounts with catalytic activity determined using probe substrates, thus allowing representation of catalysis as per pmol of UGT isoform.
authors.affiliation: Division of Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina (J.K.F., P.C.S.); and Department. of Pharmacokinetics, Dynamics, and Metabolism, Pfizer Inc., Andover, Massachusetts, (H.N.) and Groton, Connecticut, (T.C.G.).
authors.forename: John K
authors.initials: JK
authors.lastname: Fallon
authors.forename: Hendrik
authors.initials: H
authors.lastname: Neubert
authors.forename: Theunis C
authors.initials: TC
authors.lastname: Goosen
authors.forename: Philip C
authors.initials: PC
authors.lastname: Smith
mesh_terms: D002384:Catalysis; D002851:Chromatography, High Pressure Liquid / Q000379:methods; D014453:Glucuronosyltransferase / Q000737:chemistry*; D006801:Humans; D020033:Protein Isoforms / Q000737:chemistry*; D011994:Recombinant Proteins / Q000737:chemistry*; D053719:Tandem Mass Spectrometry / Q000379:methods; D000099148:UGT1A1 Enzyme
chemical_list: D014453:Glucuronosyltransferase; D020033:Protein Isoforms; D011994:Recombinant Proteins; D000099148:UGT1A1 Enzyme
references.citation: Drug Metab Dispos. 2012 Jan;40(1):83-92
references.pmid: 21994437
references.citation: J Proteome Res. 2013 Oct 4;12(10):4402-13
references.pmid: 23977844
references.citation: Nat Methods. 2013 Jan;10(1):24-7
references.pmid: 23269373
references.citation: Anal Chem. 2012 Jan 3;84(1):98-105
references.pmid: 22050083
references.citation: Hepatology. 1999 Aug;30(2):476-84
references.pmid: 10421657
references.citation: Int J Biochem Cell Biol. 2013 Jun;45(6):1121-32
references.pmid: 23500526
references.citation: Annu Rev Pharmacol Toxicol. 2000;40:581-616
references.pmid: 10836148
references.citation: Drug Metab Dispos. 2009 Jan;37(1):66-73
references.pmid: 18832477
references.citation: Drug Metab Dispos. 2007 Mar;35(3):371-80
references.pmid: 17151191
references.citation: J Clin Invest. 1994 Dec;94(6):2385-91
references.pmid: 7989595
references.citation: Methods Enzymol. 2005;400:104-16
references.pmid: 16399346
references.citation: Biochem Biophys Res Commun. 2000 Jul 14;273(3):1053-7
references.pmid: 10891370
references.citation: Drug Metab Lett. 2008 Aug;2(3):210-22
references.pmid: 19356096